Advancing cardiac surgery
Empowering surgeons
Placing innovation in the hands of your surgeon
Mitre Medical is an early stage medical device company developing the Mitral Touch®, a less invasive and safer approach to treat mitral valve regurgitation (MR) and remodel the left ventricle (LV) in patients with moderate to severe MR.
The clinical need and economic opportunity
Treating and preventing Heart Failure (HF) is the goal of the $10B structural heart market – growing to $20B by 2028. HF is characterized by a 10% enlargement of the left ventricle (LV) every year.
Empowering surgeons
Surgeons have used our Mitral Touch to reverse this deadly trend of HF enlargement by
directly reducing the LV >30% in a beating heart without opening or stopping the heart.
Exceptional clinical Results
Using the Mitral Touch, surgeons have achieved
the greatest LV reduction ever published for a beating heart therapy. (Thourani et al., 2021)
The Mitral Touch® device is currently not approved by the FDA and is not CE marked.